Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis, Meiji to End Copromotion for Ultibro, Seebri
March 16, 2021
- Takeda’s Tanigaki to Helm Nihon Pharm upon Full Acquisition
March 16, 2021
- AstraZeneca, Daiichi Sankyo to Wind Up Nexium Copromotion
March 16, 2021
- Takeda Appoints Milano Furuta as New Japan Chief
March 16, 2021
- Relumina Non-Inferior to Leuprorelin in Japan PIII Study for Endometriosis: ASKA
March 16, 2021
- Face-to-Face Promotions Down 16% in January as Pharma Switches to Online Meetings: Intage
March 16, 2021
- Kyowa Kirin Files G-Lasta for Label Expansion
March 15, 2021
- Takeda Seeks Japan Approval for HAE Med Lanadelumab
March 15, 2021
- Daiichi Sankyo Kicks Off AstraZeneca Vaccine Manufacturing in Japan
March 15, 2021
- Takeda Aims for 1 Trillion Yen Sales in Emerging Markets by FY2030
March 15, 2021
- Actemra-Remdesivir COVID-19 Combo Trial Fails, Chugai to Gauge Overall Data for Submission
March 12, 2021
- Sosei to Get US$2.5 Million Milestone Payment from Formosa
March 12, 2021
- Me Pharma Eyes Production of 1 Billion Tablets in FY2021, Sales Buoyed by Low Prices
March 12, 2021
- 5 Lysosomal Disease Drugs Now Available for Home Care: Sanofi
March 12, 2021
- Astellas Seeks Japan Nod for Padcev
March 12, 2021
- Keytruda Filed for TMB-H Solid Tumors in Japan: MSD
March 12, 2021
- Takeda, ANA to Test Drone Drug Delivery to Remote Islands in Nagasaki
March 12, 2021
- Kobayashi Kako to Invite Outsider to Take Over Top Post: Biz Improvement Plan
March 11, 2021
- Nichi-Iko to Stop Supply of 4 APIs/8 Products as Stocks Run Out
March 11, 2021
- JMA Affiliate Data Operator Poised to Provide RWD from NHO Hospitals to Drug Makers
March 11, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…